A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

Colorectal cancer: Potential treatment for drug-resistant cases A recently identified small molecule shows promise for tackling resistance to a leading colorectal cancer drug. Three proteins that are over-expressed in colorectal cancer are epidermal growth factor receptor (EGFR), RAS and β-catenin....

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sang-Kyu Lee, Yong-Hee Cho, Pu-Hyeon Cha, Jeong-Soo Yoon, Eun Ji Ro, Woo-Jeong Jeong, Jieun Park, Hyuntae Kim, Tae Il Kim, Do Sik Min, Gyoonhee Han, Kang-Yell Choi
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Publishing Group 2018-11-01
Sarja:	Experimental and Molecular Medicine
Linkit:	https://doi.org/10.1038/s12276-018-0182-2
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!